Works matching DE "DARATUMUMAB"

Results: 318
    1
    2
    3
    4

    Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies.

    Published in:
    2025
    By:
    • Theodorakakou, Foteini;
    • Fotiou, Despina;
    • Spiliopoulou, Vasiliki;
    • Migkou, Magdalini;
    • Malandrakis, Panagiotis;
    • Ntanasis-Stathopoulos, Ioannis;
    • Roussou, Maria;
    • Kanellias, Nikolaos;
    • Eleutherakis-Papaiakovou, Evangelos;
    • Solia, Eirini;
    • Papanikolaou, Asimina;
    • Gakiopoulou, Charikleia;
    • Courraud, Julie;
    • Nikolaou, Panagiota-Efstathia;
    • Giannouli, Stavroula;
    • Gavriatopoulou, Maria;
    • Terpos, Evangelos;
    • Dimopoulos, Meletios-Athanasios;
    • Kastritis, Efstathios
    Publication type:
    Letter to the Editor
    5
    6
    7
    8
    9

    Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45561-z
    By:
    • Liu, Jiye;
    • Xing, Lijie;
    • Li, Jiang;
    • Wen, Kenneth;
    • Liu, Ning;
    • Liu, Yuntong;
    • Wu, Gongwei;
    • Wang, Su;
    • Ogiya, Daisuke;
    • Song, Tian-Yu;
    • Kurata, Keiji;
    • Penailillo, Johany;
    • Morelli, Eugenio;
    • Wang, Tingjian;
    • Hong, Xiaoning;
    • Gulla, Annamaria;
    • Tai, Yu-Tzu;
    • Munshi, Nikhil;
    • Richardson, Paul;
    • Carrasco, Ruben
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00805-x
    By:
    • Moreau, Philippe;
    • Chari, Ajai;
    • Oriol, Albert;
    • Martinez-Lopez, Joaquin;
    • Haenel, Mathias;
    • Touzeau, Cyrille;
    • Ailawadhi, Sikander;
    • Besemer, Britta;
    • de la Rubia Comos, Javier;
    • Encinas, Cristina;
    • Mateos, Maria-Victoria;
    • Salwender, Hans;
    • Rodriguez-Otero, Paula;
    • Hulin, Cyrille;
    • Karlin, Lionel;
    • Sureda Balari, Anna;
    • Bargay, Joan;
    • Benboubker, Lotfi;
    • Rosiñol, Laura;
    • Tarantolo, Stefano
    Publication type:
    Article
    28
    29

    Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00655-z
    By:
    • Al Saleh, Abdullah S.;
    • Ebraheem, Mohammad S.;
    • Sidiqi, M. Hasib;
    • Dispenzieri, Angela;
    • Muchtar, Eli;
    • Buadi, Francis K.;
    • Warsame, Rahma;
    • Lacy, Martha Q.;
    • Dingli, David;
    • Gonsalves, Wilson I.;
    • Kourelis, Taxiarchis V.;
    • Hogan, William J.;
    • Hayman, Suzanne R.;
    • Kapoor, Prashant;
    • Kumar, Shaji K.;
    • Gertz, Morie A.
    Publication type:
    Article
    30

    Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.

    Published in:
    2022
    By:
    • Nooka, Ajay K.;
    • Kaufman, Jonathan L.;
    • Rodriguez, Cesar;
    • Jakubowiak, Andrzej;
    • Efebera, Yvonne;
    • Reeves, Brandi;
    • Wildes, Tanya;
    • Holstein, Sarah A.;
    • Anderson Jr, Larry D.;
    • Badros, Ashraf;
    • Shune, Leyla;
    • Chari, Ajai;
    • Pei, Huiling;
    • Cortoos, Annelore;
    • Patel, Sharmila;
    • Bartlett, J. Blake;
    • Vermeulen, Jessica;
    • Lin, Thomas S.;
    • Richardson, Paul G.;
    • Voorhees, Peter
    Publication type:
    Letter
    31

    The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM).

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 9, p. 1, doi. 10.1038/s41408-021-00548-7
    By:
    • Ho, Matthew;
    • Zanwar, Saurabh;
    • Kapoor, Prashant;
    • Gertz, Morie;
    • Lacy, Martha;
    • Dispenzieri, Angela;
    • Hayman, Suzanne;
    • Dingli, David;
    • Baudi, Francis;
    • Muchtar, Eli;
    • Leung, Nelson;
    • Kourelis, Taxiarchis;
    • Warsame, Rahma;
    • Fonder, Amie;
    • Hwa, Lisa;
    • Hobbs, Miriam;
    • Kyle, Robert;
    • Rajkumar, S. Vincent;
    • Kumar, Shaji
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 13, p. 2140, doi. 10.1080/10428194.2023.2253479
    By:
    • Eleutherakis Papaiakovou, Evangelos;
    • Terpos, Evangelos;
    • Kanellias, Nikolaos;
    • Migkou, Magdalini;
    • Gavriatopoulou, Maria;
    • Ntanasis-Stathopoulos, Ioannis;
    • Fotiou, Despoina;
    • Malandrakis, Panagiotis;
    • Theodorakakou, Foteini;
    • Spiliopoulou, Vasiliki;
    • Kostopoulos, Ioannis V.;
    • Tsitsiloni, Ourania;
    • Tsirigotis, Panagiotis;
    • Dimopoulos, Meletios-Athanasios;
    • Kastritis, Efstathios
    Publication type:
    Article
    44

    Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 10, p. 1715, doi. 10.1080/10428194.2023.2232487
    By:
    • Mele, Giuseppe;
    • Di Renzo, Nicola;
    • Cascavilla, Nicola;
    • Carella, Angelo Michele;
    • Guarini, Attilio;
    • Mazza, Patrizio;
    • Melillo, Lorella;
    • Pavone, Vincenzo;
    • Tarantini, Giuseppe;
    • Curci, Paola;
    • Falcone, Anna P.;
    • Germano, Candida;
    • Mele, Anna;
    • Merchionne, Francesca;
    • Palazzo, Giulia;
    • Palumbo, Gaetano;
    • Quinto, Angela Maria;
    • Reddiconto, Giovanni;
    • Rossini, Bernardo;
    • Spina, Alessandro
    Publication type:
    Article
    45

    Correction.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 7, p. 1358, doi. 10.1080/10428194.2023.2215574
    Publication type:
    Article
    46
    47

    Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 2, p. 468, doi. 10.1080/10428194.2022.2148221
    By:
    • Nahi, Hareth;
    • Usmani, Saad Z.;
    • Mateos, Maria-Victoria;
    • van de Donk, Niels W. C. J.;
    • Oriol, Albert;
    • Plesner, Torben;
    • Bandyopadhyay, Nibedita;
    • Hellemans, Peter;
    • Tromp, Brenda;
    • Nnane, Ivo;
    • Zemlickis, Donna;
    • Chari, Ajai;
    • Moreau, Philippe
    Publication type:
    Article
    48

    A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 14, p. 3488, doi. 10.1080/10428194.2022.2131417
    By:
    • Nath, Karthik;
    • Shekarkhand, Tala;
    • Salcedo, Meghan;
    • Derkach, Andriy;
    • Rueda, Siobhan;
    • Chansakul, Aisara;
    • Hulcrantz, Malin;
    • Korde, Neha;
    • Shah, Urvi A.;
    • Tan, Carlyn;
    • Chung, David J.;
    • Lahoud, Oscar B.;
    • Hassoun, Hani;
    • Lesokhin, Alexander M.;
    • Landau, Heather J.;
    • Shah, Gunjan;
    • Scordo, Michael;
    • Giralt, Sergio A.;
    • Usmani, Saad Z.;
    • Roshal, Mikhail
    Publication type:
    Article
    49
    50